Land: Malaysia
Sprache: Englisch
Quelle: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
CARBETOCIN
Eucogen Pharma Sdn. Bhd.
CARBETOCIN
5 vials of 1 ml
SIA PHARMIDEA
The adverse effects in the table below are presented according to the MedDRA System Organ Class database and frequency convention. System Organ Class Very Common Blood and lymphatic system disorders Nervous system disorders Headache, tremor Vascular disorders H yp otension, flushing Respiratory, thoracic and mediastinal disorders Gastrointestinal disorders Nausea, abdominal pain Skin and subcutaneous Pruritus tissue disorders Musculoskeletal and connective tissue disorders General disorders and Feeling of warmth administration site conditions Sweating and tachycardia were reported as sporadic cases. Reporting of suspected adverse reactions Common Anaemia Dizziness Chest pain, dyspnoea Metallic taste, vomiting Back pain Chills, pain Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions. _4. 9 Overdose_ Overdose of carbetocin may produce uterine h yp eractivity whether or not due to h yp ersensitivity to this agent. Hyperstimulation with strong (h yp ertonic) or prolonged (tetanic) contractions resulting from oxytocin overdose can lead to uterine rupture or postpa1tum haemorrhage. In severe cases, overdose of oxytocin may lead to h yp onatraemia and water intoxication, especially when associated with excessive concomitant fluid intake. As carbetocin is an analogue of oxytocin, the possibility of a similar event cannot be excluded. Treatment of overdose of carbetocin consists of symptomatic and supportive therapy. When signs or symptoms of overdose occur, oxygen should be given to the mother. In cases of water intoxication it is essential to restrict fluid intake, promote diuresis, correct electrolyte imbalance, and control convulsions that may eventually occur. 5 PHARMACOLOGICAL PROPERTIES _5.1 Pharmacodynamic properties _ Pharmacotherapeutic group: Oxytocin and analogues, ATC code: H01BB03 The pharmacological and Lesen Sie das vollständige Dokument